aim
investig
effect
massiv
dose
corticosteroid
therapi
bone
metabol
use
specif
biochem
marker
bone
metabol
preval
osteonecrosi
sever
acut
respiratori
syndrom
sar
patient
univers
teach
hospit
hong
kong
method
seventyon
patient
clinic
diagnosi
sar
studi
accord
modifi
world
health
organ
case
definit
sar
involv
sar
epidem
march
june
clinic
diagnosi
confirm
serolog
test
molecular
analysi
biochem
marker
bone
metabol
analys
retrospect
use
serial
clot
blood
sampl
collect
patient
cours
hospit
admiss
discharg
subsequ
followup
outpati
clinic
use
arbitrari
time
period
day
ii
day
iii
day
iv
day
onset
fever
magnet
reson
imag
knee
hip
joint
perform
postadmiss
evalu
preval
osteonecrosi
amongst
sar
patient
variou
risk
factor
develop
osteonecrosi
assess
use
receiv
oper
characterist
curv
comparison
appropri
test
statist
spearman
coeffici
rank
correl
biochem
bone
marker
result
biochem
marker
bone
metabol
show
signific
bone
resorpt
evidenc
mark
increas
serum
ctermin
telopeptid
concentr
ctx
day
onset
fever
taper
corticosteroid
dosag
ctx
start
return
previou
baselin
level
day
onward
bone
format
marker
serum
osteocalcin
bonespecif
alkalin
phosphatas
concentr
oc
balp
respect
start
increas
latter
effect
even
mark
day
seven
patient
develop
radiolog
evid
osteonecrosi
preval
osteonecrosi
cohort
total
corticosteroid
dosag
mg
hydrocortison
mg
methylprednisolon
mg
hydrocortisoneequival
corticosteroid
therapi
day
corticosteroid
therapi
found
signific
risk
factor
subsequ
develop
osteonecrosi
also
signific
posit
correl
amongst
variou
biochem
bone
marker
patient
cohort
conclus
bone
resorpt
format
marker
unabl
predict
subsequ
develop
osteonecrosi
use
high
dose
hydrocortison
methylprednisolon
extend
durat
shown
signific
risk
factor
osteonecrosi
preval
cohort
compar
report
literatur
sar
patient
highdos
corticosteroid
therapi
day
increas
serum
ctx
coincid
time
corticosteroid
use
day
increas
serum
oc
balp
coincid
time
corticosteroid
withdraw
aim
investig
effect
massiv
dose
corticosteroid
therapi
bone
metabol
use
specif
biochem
marker
bone
metabol
preval
osteonecrosi
sever
acut
respiratori
syndrom
sar
patient
univers
teach
hospit
hong
kong
method
seventyon
patient
clinic
diagnosi
sar
studi
accord
modifi
world
health
organ
case
definit
sar
involv
sar
epidem
march
june
clinic
diagnosi
confirm
serolog
test
molecular
analysi
biochem
marker
bone
metabol
analys
retrospect
use
serial
clot
blood
sampl
collect
patient
cours
hospit
admiss
discharg
subsequ
followup
outpati
clinic
use
arbitrari
time
period
day
ii
day
iii
day
iv
day
onset
fever
magnet
reson
imag
knee
hip
joint
perform
postadmiss
evalu
preval
osteonecrosi
amongst
sar
patient
variou
risk
factor
develop
osteonecrosi
assess
use
receiv
oper
characterist
curv
comparison
appropri
test
statist
spearman
coeffici
rank
correl
biochem
bone
marker
result
biochem
marker
bone
metabol
show
signific
bone
resorpt
evidenc
mark
increas
serum
ctermin
telopeptid
concentr
ctx
day
onset
fever
taper
corticosteroid
dosag
ctx
start
return
previou
baselin
level
day
onward
bone
format
marker
serum
osteocalcin
bonespecif
alkalin
phosphatas
concentr
oc
balp
respect
start
increas
latter
effect
even
mark
day
seven
patient
develop
radiolog
evid
osteonecrosi
preval
osteonecrosi
cohort
total
corticosteroid
dosag
mg
hydrocortison
mg
methylprednisolon
mg
hydrocortisoneequival
corticosteroid
therapi
day
corticosteroid
therapi
found
signific
risk
factor
subsequ
develop
osteonecrosi
also
signific
posit
correl
amongst
variou
biochem
bone
marker
patient
cohort
conclus
bone
resorpt
format
marker
unabl
predict
subsequ
develop
osteonecrosi
use
high
dose
hydrocortison
methylprednisolon
extend
durat
shown
signific
risk
factor
osteonecrosi
preval
cohort
compar
report
literatur
sar
patient
highdos
corticosteroid
therapi
day
increas
serum
ctx
coincid
time
corticosteroid
use
day
increas
serum
oc
balp
coincid
time
corticosteroid
withdraw
use
massiv
dose
corticosteroid
criticis
potenti
advers
effect
variou
organ
system
includ
cardiovascular
endocrin
skelet
central
nervou
system
apart
target
immunosuppress
highdos
corticosteroid
use
salvag
therapi
refractori
adult
respiratori
distress
syndrom
ard
typic
dosag
rang
mg
methylprednisolon
per
kg
bodi
weight
daili
kg
patient
ard
amount
corticosteroid
receiv
would
equival
mg
hydrocortison
per
day
time
normal
daili
product
adult
adren
gland
highdos
inhal
corticosteroid
prepubert
asthmat
children
associ
compromis
bone
miner
densiti
may
potenti
risk
fractur
futur
patient
system
lupu
erythematosu
sle
role
daili
oral
corticosteroid
therapi
pathogenesi
osteonecrosi
well
recognis
oral
nonbolu
corticosteroid
therapi
treatment
sle
shown
correl
strongli
osteonecrosi
recent
prospect
studi
patient
sle
show
develop
osteonecrosi
intraven
puls
corticosteroid
oral
prednisolon
therapi
dose
mgday
least
month
risk
factor
osteonecrosi
howev
unclear
whether
shortterm
highdos
methylprednisolon
puls
therapi
risk
factor
recent
outbreak
sever
acut
respiratori
syndrom
sar
hong
kong
corticosteroid
prescrib
acut
phase
infect
mainten
corticosteroid
use
either
intraven
hydrocortison
oral
prednisolon
offer
sar
patient
respond
convent
antivir
antimicrobi
agent
highdos
puls
methylprednisolon
prescrib
addit
mainten
therapi
deterior
clinic
use
corticosteroid
withhold
least
allevi
alleg
cytokin
chemokin
storm
induc
sarsassoci
coronaviru
sarscov
therebi
prevent
massiv
tissu
destruct
organ
damag
howev
dosag
methylprednisolon
use
document
literatur
salvag
therapi
ard
shortterm
highdos
glucocorticoid
therapi
ineffect
ard
steroid
usag
sar
also
question
studi
biochem
marker
bone
metabol
use
retrospect
investig
effect
massiv
dose
puls
mainten
corticosteroid
therapi
patient
sar
discharg
hospit
patient
follow
medic
outpati
clinic
magnet
reson
imag
assess
knee
hip
joint
document
osteonecrot
chang
seventyon
patient
princ
wale
hospit
hong
kong
clinic
present
fulfil
world
health
organ
criteria
probabl
sar
involv
sar
epidem
march
june
includ
studi
present
fever
cough
breath
difficulti
contact
histori
within
day
prior
onset
symptom
lymphopenia
subsequ
develop
pneumonia
evidenc
chest
radiographi
comput
tomographi
ct
thorax
diagnosi
sar
subsequ
confirm
either
serolog
detect
specif
antibodi
sarscov
demonstr
sarscov
use
reversetranscriptas
polymeras
chain
reaction
techniqu
previou
histori
bone
diseas
includ
paget
diseas
bone
fractur
osteoporosi
diseas
affect
bone
metabol
endstag
renal
failur
thyrotoxicosi
hyperparathyroid
sar
patient
given
follow
treatment
accord
hospit
protocol
first
day
admiss
ribavirin
given
either
oral
g
three
time
daili
load
dose
g
intraven
mg
everi
h
complet
cours
levofloxacin
cefotaxim
supplement
cover
bacteri
chest
infect
persist
fever
third
day
admiss
mainten
steroid
therapi
start
use
either
oral
prednisolon
mgkg
bodi
weight
daili
intraven
hydrocortison
mg
everi
h
stepdown
titrat
start
third
week
admiss
patient
clinic
deterior
includ
desatur
oxygen
satur
use
puls
oximetri
develop
new
infiltr
chest
radiograph
puls
steroid
use
methylprednisolon
g
daili
day
given
puls
methylprednisolon
therapi
repeat
clinic
indic
serum
sampl
retriev
sar
serum
bank
univers
hospit
follow
time
period
use
day
fever
onset
day
day
baselin
ii
day
receiv
corticosteroid
therapi
iii
day
discharg
hospit
iv
day
outpati
followup
sampl
studi
depend
avail
blood
sampl
arriv
laboratori
icewat
bath
centrifug
immedi
sera
aliquot
storag
analysi
serum
osteocalcin
oc
ctermin
telopeptid
type
collagen
ctx
concentr
measur
use
electrochemiluminesc
immunoassay
modular
analys
roch
diagnost
usa
bone
format
resorpt
marker
respect
antibodi
use
measur
oc
detect
intact
osteocalcin
oc
nmid
fragment
oc
anoth
bone
format
marker
serum
bonespecif
alkalin
phosphatas
balp
concentr
measur
patient
sampl
use
chemiluminesc
enzym
immunoassay
access
analys
beckmancoult
usa
interassay
coeffici
variat
low
normal
high
concentr
mgl
serum
oc
mgl
serum
ctx
mgl
serum
balp
respect
least
signific
chang
valu
concentr
mgl
serum
oc
mgl
serum
ctx
mgl
serum
balp
respect
marker
bone
metabol
use
enzymelink
immunosorb
assay
elisa
method
perform
potenti
infecti
hazard
due
aerosol
gener
magnet
reson
imag
mri
perform
sar
patient
part
screen
program
postsar
followup
assess
institut
use
magnetom
instrument
siemen
germani
median
time
admiss
mri
examin
month
rang
hip
spinecho
coron
sequenc
obtain
slice
thick
mm
intersect
gap
mm
field
view
mm
matrix
knee
spinecho
coron
sequenc
obtain
slice
thick
mm
intersect
gap
mm
field
view
mm
matrix
detail
mri
examin
perform
within
week
patient
show
evid
osteonecrosi
screen
mri
detail
mri
examin
individu
evalu
affect
hip
knee
joint
use
standard
coil
orthogon
plane
lesion
hip
spir
obliqu
coron
sagitt
imag
obtain
lesion
knee
spir
coron
intermediateweight
sagitt
imag
well
intermediateweight
spir
axial
imag
obtain
mri
examin
interpret
two
experienc
musculoskelet
radiologist
jfg
gea
find
reach
consensu
osteonecrosi
defin
subchondr
intramedullari
area
demarc
distinct
hypointens
margin
rim
encompass
medullari
fat
centr
concentr
biochem
bone
marker
measur
patient
sampl
divid
four
group
accord
time
blood
collect
describ
previous
nonparametr
mannwhitney
u
statist
pair
data
comput
bone
marker
measur
differ
time
period
one
anoth
area
receiv
oper
characterist
roc
curv
auc
confid
interv
ci
cutoff
valu
posit
likelihood
ratio
lr
well
oneway
analysi
varianc
anova
continu
variabl
fisher
exact
test
statist
categor
variabl
comput
variou
risk
factor
osteonecrosi
spearman
coeffici
rank
correl
ci
amongst
biochem
bone
marker
variou
risk
factor
osteonecrosi
also
comput
data
analys
perform
use
medcalc
statist
programm
version
medcalc
belgium
probabl
p
twotail
p
valu
consid
statist
signific
patient
demograph
data
number
patient
admit
intens
care
unit
icu
number
patient
without
puls
methylprednisolon
therapi
cumul
dose
mainten
puls
corticosteroid
therapi
averag
dose
hydrocortisoneequival
corticosteroid
per
hospit
day
summaris
tabl
male
femal
age
year
median
interquartil
rang
iqr
includ
retrospect
studi
health
care
worker
includ
medic
doctor
nurs
health
care
assist
one
occup
therapist
rest
consist
nine
medic
student
exist
hospit
patient
three
rel
health
care
profession
confirm
sar
patient
involv
initi
outbreak
sar
hong
kong
six
male
seven
femal
requir
admiss
intens
care
unit
except
patient
receiv
puls
methylprednisolon
therapi
median
iqr
dose
intraven
hydrocortison
oral
prednisolon
mainten
therapi
well
oral
methylprednisolon
puls
therapi
mg
respect
median
iqr
dose
hydrocortisoneequival
corticosteroid
therapi
prescrib
patient
calcul
mg
use
convers
factor
mg
methylprednisolon
equal
mg
hydrocortison
mg
prednisolon
equal
mg
hydrocortison
median
iqr
hospitalday
mainten
andor
puls
corticosteroid
therapi
day
result
daili
averag
hydrocortisoneequival
dose
iqr
mgday
time
normal
daili
product
adren
gland
plot
percentag
chang
baselin
serum
biochem
marker
bone
metabol
shown
fig
median
join
straight
line
error
bar
defin
confid
interv
median
asterisk
denot
signific
chang
baselin
day
valu
use
nonparametr
mannwhitney
u
test
statist
compar
baselin
concentr
day
signific
increas
chang
median
concentr
serum
ctx
day
find
coincid
greatest
frequenc
puls
corticosteroid
use
withdraw
puls
mainten
corticosteroid
commenc
replac
dosag
serum
ctx
start
return
previou
baselin
concentr
day
onward
significantli
differ
compar
day
peak
bone
loss
promin
signific
differ
serum
ctx
among
day
day
day
serum
oc
start
increas
reach
statist
signific
differ
day
onward
elev
even
mark
day
serum
balp
essenti
follow
trend
serum
oc
concentr
start
rise
earlier
day
reach
statist
signific
differ
day
serum
balp
appear
increas
continu
without
reach
statist
signific
differ
howev
day
onward
increas
serum
balp
mark
signific
differ
compar
baselin
day
concentr
followup
period
one
patient
die
exist
medic
ill
one
patient
refus
mri
assess
osteonecrosi
due
absenc
symptom
therefor
total
number
corticosteroidtr
patient
follow
repeat
mri
examin
patient
patient
complain
symptomat
bone
joint
pain
seven
develop
radiolog
evid
osteonecrosi
includ
three
male
four
femal
age
year
median
iqr
mri
find
osteonecrosi
one
femal
postsar
patient
present
fig
show
subchondr
abnorm
anterosuperior
aspect
femor
head
demarc
hypointens
rim
similar
intramedullari
subchondr
area
osteonecrosi
right
knee
result
spearman
coeffici
rank
correl
r
ci
amongst
biochem
bone
marker
summaris
tabl
signific
correl
ctx
balp
r
ci
oc
balp
r
ci
well
signific
neg
correl
oc
age
r
ci
howev
signific
correl
serum
ctx
oc
variou
bone
marker
risk
factor
osteonecrosi
best
knowledg
first
report
specif
biochem
marker
bone
metabol
studi
sar
patient
treat
shortterm
highdos
corticosteroid
shown
close
tempor
relationship
serial
chang
serum
biochem
bone
marker
sar
patient
puls
corticosteroid
therapi
initi
mark
increas
serum
ctx
day
could
repres
immedi
osteoporot
effect
corticosteroid
bone
metabol
puls
methylprednisolon
given
withdraw
corticosteroid
therapi
commenc
replac
dose
around
day
onward
serum
ctx
start
return
baselin
level
major
studi
patient
formerli
healthi
individu
previou
histori
bone
diseas
paget
diseas
bone
fractur
osteoporosi
diseas
affect
bone
metabol
exampl
endstag
renal
failur
thyrotoxicosi
hyperparathyroid
none
previous
corticosteroid
therapi
acut
phase
sar
infect
treat
highdos
corticosteroid
therapi
subsequ
followup
seven
patient
develop
osteonecrosi
even
though
nearli
half
complain
bone
joint
pain
indic
symptom
alon
good
predictor
subsequ
develop
osteonecrosi
therefor
variou
factor
risk
assess
osteonecrosi
studi
auc
ci
peak
serum
ctx
oc
balp
predict
subsequ
develop
osteonecrosi
respect
auc
ci
ratio
bone
format
bone
resorpt
marker
peak
serum
oc
ctx
balp
ctx
ratio
respect
none
signific
risk
predictor
develop
osteonecrosi
also
signific
differ
chang
bone
turnov
marker
osteonecrot
nonosteonecrot
patient
group
contrari
cumul
dose
mg
methylprednisolon
found
best
predictor
osteonecrosi
amongst
signific
risk
factor
highest
posit
likelihood
ratio
therefor
suggest
shortterm
highdos
puls
methylprednisolon
histori
puls
corticosteroid
use
one
import
risk
factor
osteonecrosi
report
previous
howev
statist
signific
differ
auc
amongst
risk
factor
name
total
dose
mg
hydrocortison
mg
hydrocortisoneequival
day
corticosteroid
therapi
reanalysi
auc
methylprednisolon
treatment
use
multipl
roc
curv
comparison
interestingli
neither
posit
histori
admiss
intens
care
unit
high
degre
immobilis
due
need
respiratori
support
posit
histori
puls
methylprednisolon
use
found
signific
risk
factor
subsequ
develop
osteonecrosi
steroidinduc
osteonecrosi
frequent
case
involv
hip
impos
signific
morbid
devast
disabl
estim
preval
last
decad
renal
transplant
recipi
sle
patient
may
develop
patient
receiv
steroid
high
shortterm
dose
longterm
dose
even
intraarticular
inject
interv
corticosteroid
administr
onset
symptom
rare
less
six
month
may
three
year
korean
studi
time
develop
osteonecrosi
steroid
therapi
report
month
median
median
time
admiss
mri
examin
cohort
month
rang
compar
literatur
data
preval
steroidinduc
osteonecrosi
around
cohort
sar
patient
involv
earliest
outbreak
treat
hospit
also
compar
preval
report
literatur
higher
overal
result
sar
patient
hospit
includ
plausibl
explan
could
judici
use
ribavirincorticosteroid
combin
therapi
respiratori
decompens
stage
toward
end
sar
epidem
hong
kong
much
clinic
experi
accumul
later
stage
sar
epidem
hong
kong
convalesc
sera
donat
recov
sar
patient
avail
serv
anoth
treatment
modal
corticosteroid
dose
could
therebi
lower
accordingli
minimis
risk
osteonecrosi
subsequ
increas
serum
concentr
bone
format
marker
oc
balp
suggest
osteoblast
activ
tempor
delay
peak
bone
resorpt
even
though
osteoblast
treat
highdos
corticosteroid
bone
remodel
mechan
still
activ
initi
breakdown
boni
substanc
osteoclast
coupl
osteoblast
would
activ
enter
prolif
phase
although
imposs
separ
matrix
synthesi
mineralis
phase
current
biochem
marker
technolog
enhanc
express
alkalin
phosphatas
immedi
follow
prolif
period
later
increas
express
osteocalcin
osteopontin
onset
mineralis
hypothesis
thu
signific
increas
serum
balp
day
oc
day
onward
may
suggest
live
osteoblast
tri
replenish
previou
bone
loss
effect
corticosteroid
bone
metabol
could
transient
revers
serum
peak
ctx
balp
concentr
posit
associ
r
differ
time
sequenc
fig
c
repres
coupl
bone
resorpt
follow
bone
format
normal
bone
remodel
process
biochem
marker
bone
format
amount
osteocalcin
releas
thought
repres
osteoblast
activ
bone
mineralis
phase
newli
synthesis
protein
incorpor
bone
matrix
osteocalcin
function
bind
calcium
mineralis
process
also
requir
presenc
balp
involv
breakdown
pyrophosph
without
balp
pyrophosph
inhibit
deposit
calcium
phosphat
ion
onto
extracellular
matric
therefor
surpris
serum
concentr
two
biochem
bone
marker
oc
balp
posit
associ
r
repres
physiolog
coupl
new
bone
matrix
synthesi
mineralis
phase
normal
bone
remodel
process
limit
studi
could
retriev
sera
remain
sar
serum
bank
studi
biochem
bone
marker
sampl
use
serolog
molecular
diagnosi
sar
infect
well
sarsrel
research
conclus
preval
osteonecrosi
sar
patient
treat
highdos
shortterm
corticosteroid
bone
marker
resorpt
format
unabl
predict
subsequ
develop
cumul
dose
mg
methylprednisolon
mg
hydrocortison
mg
hydrocortison
equival
day
corticosteroid
therapi
signific
risk
predictor
osteonecrosi
puls
steroid
therapi
biochem
bone
marker
use
studi
pathophysiolog
bone
metabol
respons
massiv
dose
corticosteroid
